Toxicity Management Critical for Oncology BsAbs

By Marcus A. Banks Giuseppe Curigliano, MD, PhDBispecific antibodies (BsAbs), which simultaneously target multiple antigens to generate an immune response, can improve health outcomes and quality of life for people with cancer. However, managing toxicities from this form of immunotherapy is critical, according to a presentation at the 2025 ASCO Annual Meeting, in Chicago, by Giuseppe Curigliano, MD, PhD. Dr. Curigliano, the president-elect of the European Society for Medical Oncology, directs ea